MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..


Company: Amgen
Approval Status: Approval April 1998
Treatment for: slow white blood cell recovery following chemotherapy
Areas: Hematology; Cancer & Oncology

| General Information |

General Information

Neupogen has been approved for its fifth indication: to reduce the time to neutrophil recovery and the duration of fever following chemotherapy treatment in patients being treated for acute myeologenous leukemia. Patients with this type of leukemia can now receive Neupogen to improve their ability to tolerate essential chemotherapy treatments.

< back to top

Neupogen Drug Information

The Neupogen drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2016 All rights reserved.